1. Executive Summary
1.1 Biological Drugs Market Review
1.2 Contents of This Report
1.3 Research and Analysis Methods
2. Overview of the Biological Drugs Market 2011-2021
2.1 The Biological Drugs Market Was Worth over $100bn in 2010
2.2 Market Forecast 2011-2021
2.3 Biological Drugs versus Small Molecules
2.4 Creating Biological Drugs
2.5 Defining the Biotechnology Space
2.6 What is a Biopharmaceutical?
2.7 Vaccines
3. Monoclonal Antibodies Market 2011-2021
3.1 Monoclonal Antibodies in 2009
3.2 The Science of Antibodies
3.3 Murine, Chimeric, Humanised and Fully-Human MAbs
3.4 Prospects for the Monoclonal Antibodies Market
3.5 Top Products in the MAbs Market
3.5.1 Remicade (Johnson & Johnson) 2011-2021
3.5.2 Avastin (Roche) 2011-2021
3.5.3 Rituxan (Roche) 2011-2021
3.5.4 Humira (Abbott) 2011-2021
3.5.5 Herceptin (Roche) 2011-2021
3.5.6 Lucentis (Roche) 2011-2021
3.5.7 Erbitux (Eli Lilly) 2011-2021
3.5.8 Synagis (AstraZeneca) 2011-2021
3.5.9 Tysabri (Biogen Idec) 2011-2021
3.5.10 Xolair (Roche) 2011-2021
4. Therapeutic Proteins Market 2011-2021
4.1 Overall Prospects for Therapeutic Proteins Sector
4.2 Insulin and Insulin Analogues
4.3 Erythropoietins
4.4 Interferons
4.5 Granular-Colony Stimulating Factors (G-CSF)
4.6 Recombinant Coagulation Factors
4.7 Top Products in the Therapeutic Proteins Market
4.7.1 Enbrel (Amgen) 2011-2021
4.7.2 Epogen (Amgen) 2011-2021
4.7.3 Lantus (Sanofi-Aventis) 2011-2021
4.7.4 Neulasta (Amgen) 2011-2021
4.7.5 Aranesp (Amgen) 2011-2021
4.7.6 Avonex (Biogen Idec) 2011-2021
4.7.7 Rebif (Merck Serono) 2011-2021
4.7.8 Advate (Baxter Healthcare) 2011-2021
4.7.9 Humalog (Eli Lilly) 2011-2021
4.7.10 Novorapid (Novo Nordisk) 2011-2021
5. Biosimilars Market 2011-2021
5.1 Forecast for Biosimilars Market, 2011-2021
5.2 Overview of the Biosimilars Market in 2011
5.3 Biosimilar Monoclonal Antibodies
5.4 Biosimilar Insulins
5.5 Biosimilar Erythropoietins
5.6 Biosimilar Interferons
5.7 Biosimilar G-CSF
6. R&D Pipelines for Biological Drugs
6.1 MAbs
6.2 Dalotuzumab (Merck & Co)
6.3 MAb, CCR4 (Amgen)
6.4 MAb, VEGFR-2 (UCB)
6.5 Ramucirumab (Eli Lilly)
6.6 Necitumumab (Eli Lilly)
6.7 Ipilimumab (Bristol-Myers Squibb)
6.8 Tanezumab (Roche)
6.9 Trastuzumab Emtansine (Roche)
6.10 Numax (AstraZeneca)
6.11 Benlysta (Human Genome Sciences/ GSK)
6.12 Ocrelizumab (Roche/ Biogen Idec)
6.13 Denosumab (Amgen)
6.14 Bapineuzumab (Pfizer/ Johnson & Johnson)
6.15 Solanezumab (Eli Lilly)
6.16 Asthma MAb (BioWa)
6.17 Rabies MAb (Crucell/ Merck & Co.)
6.18 Therapeutic Proteins
6.19 Recombinant Human Factor XIII (Novo Nordisk)
6.20 Juvista (Shire)
6.21 Belatacept (Bristol-Myers Squibb)
7. Leading Companies in the Biological Drugs Market
7.1 Roche Controls Nearly a Quarter of the Biological Drugs Market
7.1.1 Roche
7.1.2 Amgen
7.1.3 Johnson & Johnson
7.1.4 Novo Nordisk
7.1.5 Abbott
7.2 Biopharmaceutical M&A
7.2.1 Mega-Mergers
7.2.2 Smaller Acquisitions
7.3 Major Pharma's Emphasis on Biological Drugs
7.3.1 Pfizer
7.3.2 AstraZeneca
7.3.3 Merck & Co.
7.3.4 Novartis
7.3.5 Sanofi-Aventis
7.3.6 Eli Lilly
7.3.7 GlaxoSmithKline
7.3.8 Teva
8. Leading Countries in the Biological Drugs Market
8.1 Leading Biologic Drug National Markets in 2009
8.2 Forecast for National Markets 2011-2021
8.3 The US
8.3.1 The US: Market Forecast 2011-2021
8.4 Europe
8.4.1 Europe: Market Outlook 2011-2021
8.4.2 France: Market Forecast 2011-2021
8.4.3 Germany: Market Forecast 2011-2021
8.4.4 UK: Market Forecast 2011-2021
8.4.5 Italy: Market Forecast 2011-2021
8.4.6 Spain: Market Forecast 2011-2021
8.5 Japan
8.5.1 Japan: Market Forecast 2011-2021
8.6 China
8.6.1 China: Market Forecast 2011-2021
8.7 India
8.7.1 India: Market Forecast 2011-2021
9. Expert Opinion
9.1 Interview with Ronald A. Rader, President, Biotechnology Information Institute
9.1.1 On Defining 'Biopharmaceutical'
9.1.2 On the Future of Biological Drugs
9.1.3 On Lack of Information Resources in the Pharma Industry
9.1.4 On the Regulatory Uncertainty Surrounding Biopharmaceuticals and Biosimilars
9.1.5 On the Potential and the Problems of Biosimilars
9.2 Interview with Dr Janice Reichert, Editor-in-Chief, MAbs
9.2.1 On the Reasons for the Ascendancy of MAbs
9.2.2 On the Current Indications for MAbs
9.2.3 On Antibody-Drug Conjugates and Bispecifics
9.2.4 On Non-Human Antibodies and Alternative Scaffolds
9.2.5 On the Prospects for Biosimilar Antibodies
9.3 Interview with Steven A. Grossman, President, HPS Group, LLC
9.3.1 On the US Biosimilar Industry in the Next Decade
9.3.2 On Different Pathways to Biosimilar Approval
9.3.3 On the Legislation's Effect on Innovative Biological Drugs
9.4 Interview with Dr James DeGiulio, Expert on Patent Applications and Biotechnology Litigation
9.4.1 On the US Biosimilars Pathway
9.4.2 On the Comparison between US and European Biosimilar Markets
9.4.3 On the Challenges for Biosimilars
9.4.4 On the Regulatory Challenges for Innovative Biopharmaceuticals
10. SWOT Analysis of the Biological Drugs Market and Conclusions
10.1 Strengths
10.1.1 The Biological Drugs Market is Well-Established
10.1.2 Biological Products Bring High Revenues for the Industry
10.1.3 Biopharmaceuticals Target Important Therapeutic Areas
10.2 Weaknesses
10.2.1 Biological Drugs Are Costly
10.2.2 The Biologicals Industry is Insufficiently Dynamic?
10.2.3 The Biosimilar Industry - How Will it Affect the Biologics Industry?
10.3 Opportunities
10.3.1 Biosimilars are a Major Growth Opportunity
10.3.2 The Biosimilars Market is Open
10.3.3 Opportunities Remain in the Patented Biopharmaceutical Sector
10.4 Threats
10.4.1 Cost-Cutting Measures May Endanger Biopharmaceutical Growth
10.4.2 There are Outstanding Health Concerns with Some Biological Products
10.4.3 Clearer Regulatory Policy Would Benefit the Biologics Industry
10.5 Concluding Remarks
List of Tables
Table 2.1 Biological Drugs Market, Revenues ($bn), Shares of Overall Pharmaceutical Market, 2009
Table 2.2 Sectors of the Biological Drugs Market, Revenues ($bn), Market Shares (%) 2009
Table 2.3 Global Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 2.4 Global Biological Drugs Market by Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 2.5 Strengths and Weaknesses of Biological Drugs Compared with Small-Molecule Drugs
Table 3.1 Monoclonal Antibodies, Revenues ($bn), 2009
Table 3.2 Monoclonal Antibodies Market by Indication, Revenues ($bn), Market Shares (%), 2009
Table 3.3 Monoclonal Antibodies Market, Revenues ($bn), Annual Growth (%), CAGR (%), Shares of Biological Drug Market (%), 2009-2021
Table 3.4 Remicade Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.5 Avastin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.6 Rituxan Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.7 Humira Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.8 Herceptin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.9 Lucentis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.10 Erbitux Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.11 Synagis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.12 Tysabri Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.13 Xolair Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.1 Therapeutic Proteins Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.2 Insulins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.3 Erythropoietins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.4 Interferons Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.5 G-CSF Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.6 Recombinant Coagulation Factors Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.7 Enbrel, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.8 Epogen, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.9 Lantus, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.10 Neulasta, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.11 Aranesp, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.12 Avonex, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.13 Rebif, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.14 Advate, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.15 Humalog, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.16 NovoRapid, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 5.1 Biosimilars Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), Market Shares (%), Lead Products, 2009
Table 8.1 Top Countries in the Biological Drugs Market, Revenues ($bn), Market Shares (%)
Table 8.2 Regions in the Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.3 US: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.4 European Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.5 France: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.6 Germany: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.7 UK: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.8 Spain: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.9 Italy: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.10 Japan: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.11 China: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 8.12 India: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 10.1 SWOT Analysis of the Biological Drugs Market, 2011
List of Figures
Figure 2.1 Biological and Non-Biological Drugs Markets, Revenues ($bn), 2009
Figure 2.2 Sectors of the Biological Drugs Industry, Market Shares, 2009
Figure 2.3 Global Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 2.4 Sectors of the Biological Drugs Industry, Market Shares, 2021
Figure 2.5 Global Biological Drugs Market by Sector, Revenues ($bn), 2009-2021
Figure 3.1 Monoclonal Antibodies, Revenues ($bn), Other Biological Drugs Market Revenues ($bn), 2009
Figure 3.2 Monoclonal Antibodies, Revenues ($bn), Total Pharmaceutical Market Revenues ($bn), 2009
Figure 3.3 Monoclonal Antibodies, Indications, Revenues ($bn), 2009
Figure 3.4 Monoclonal Antibodies, Market Revenues ($bn), 2009-2021
Figure 3.5 Remicade Revenues ($bn), 2009-2021
Figure 3.6 Avastin Revenues ($bn), 2009-2021
Figure 3.7 Rituxan Revenues ($bn), 2009-2021
Figure 3.8 Humira Revenues ($bn), 2009-2021
Figure 3.9 Herceptin Revenues ($bn), 2009-2021
Figure 3.10 Lucentis Revenues ($bn), 2009-2021
Figure 3.11 Erbitux Revenues ($bn), 2009-2021
Figure 3.12 Synagis Revenues ($bn), 2009-2021
Figure 3.13 Tysabri Revenues ($bn), 2009-2021
Figure 3.14 Xolair Revenues ($bn), 2009-2021
Figure 4.1 Therapeutic Proteins: Revenues ($bn), 2009-2021
Figure 4.2 Insulins, Revenues ($bn), 2009-2021
Figure 4.3 Erythropoietins, Revenues ($bn), 2009-2021
Figure 4.4 Interferons, Revenues ($bn), 2009-2021
Figure 4.5 G-CSF, Revenues ($bn), 2009-2021
Figure 4.6 Recombinant Coagulation Factors, Revenues ($bn), 2009-2021
Figure 4.7 Enbrel, Revenues ($bn), 2009-2021
Figure 4.8 Epogen, Revenues ($bn), 2009-2021
Figure 4.9 Lantus, Revenues ($bn), 2009-2021
Figure 4.10 Neulasta, Revenues ($bn), 2009-2021
Figure 4.11 Aranesp, Revenues ($bn), 2009-2021
Figure 4.12 Avonex, Revenues ($bn), 2009-2021
Figure 4.13 Rebif, Revenues ($bn), 2009-2021
Figure 4.14 Advate, Revenues ($bn), 2009-2021
Figure 4.15 Humalog, Revenues ($bn), 2009-2021
Figure 4.16 NovoRapid, Revenues ($bn), 2009-2021
Figure 5.1 Biosimilars Sector Revenues ($bn), 2009-2021
Figure 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), 2009
Figure 8.1 Regions in the Biological Drugs Market, Revenues ($bn), 2009
Figure 8.2 US Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.3 European Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.4 France: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.5 Germany: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.6 UK: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.7 Spain: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.8 Italy: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.9 Japan: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.10 China: Biological Drugs Market, Revenues ($bn), 2009-2021
Figure 8.11 India: Biological Drugs Market, Revenues ($bn), 2009-2021